A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer

Conditions:   Esophageal Cancer;   Squamous Cell Esophagus Cancer;   Adenocarcinoma Esophagus
Intervention:   Drug: Pembrolizumab
Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified November 2016

http://ift.tt/2f6pvjC